Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
FAQ
An investigation from Egypt cites early systemic immunomodulation for recent localized vitiligo as a “successful approach” for achieving early control of disease activity. It helps to achieve early control of disease activity as well as minimize the incidence of recurrence. Early management of such cases is crucial; it is a race against time:
- Disease activity is arrested following 3.65 ± 2.19 months of treatment.
- Patients achieve complete repigmentation in a mean span of 6.88 ± 0.2 months.
- Recurrence is seen in 32% of patients at the end of the 4-year follow up.
- Despite recurrence, a localized disease was secured.
FAQOther Questions
- Which skin conditions can be mistaken for vitiligo?
Vitiligo is a common skin condition with characteristic milky white patches of irregular shape. However, several other skin conditions exhibit similar symptoms that can lead to ...
- I have vitiligo: will my children have vitiligo, too?
Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children with...
- Is it possible to stop the progression of vitiligo?
It is true that vitiligo progression could be stopped in 4 out of 5 cases by the use of potent systemic corticosteroids - that is, oral medications. However, systemic corticost...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.